ArticleHereditas2025
Investigating the effect of tenuigenin on LPS-induced HPMEC dysfunction by inhibiting SRC activation based on network pharmacology and molecular docking.
Article in Hereditas, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAdult pneumonia is an infectious lung disease caused by bacteria, viruses, or other microorganisms and exhibits some degree of contagion. Tenuigenin, a bioactive compound derived from Polygala tenuifolia, possesses broad pharmacological effects, but its role in adult pneumonia remains incompletely understood.
methodsBioinformatics and database analysis were employed to screen and analyze the Tenuigenin target genes relevant to adult pneumonia. Cell functions were assessed using cell counting kit-8 (CCK8), 5-ethynyl-2'-deoxyuridine (EdU) staining, transwell, tube formation, Fluo-4 calcium assay, and transepithelial electrical resistance (TER) assays. Protein levels were measured by western blot. Network pharmacology and molecular docking were employed to screen core target genes and verify binding interactions.
resultsTenuigenin targets in adult pneumonia were enriched in the pathways related to vascular permeability and calcium signaling. Tenuigenin mitigated lipopolysaccharide (LPS)-induced impairment of human pulmonary microvascular endothelial cell (HPMEC) viability, proliferation, migration, and angiogenesis, while attenuating LPS-induced increases in apoptosis, calcium ion, and reactive oxygen species (ROS) levels. Besides, Tenuigenin also attenuated the TER decrease and permeability increase caused by LPS exposure in HPMECs. Network pharmacology and molecular docking identified steroid receptor coactivator (SRC) as a core target of Tenuigenin, demonstrating binding to specific SRC amino acid residues. Tenuigenin also reduced LPS-induced increase in phosphor-SRC (p-SRC) expression. Crucially, after inhibition of SRC kinase activity, Tenuigenin no longer exerted significant protective effects against LPS-induced HPMEC injury and dysfunction.
conclusionTenuigenin alleviates LPS-induced injury and dysfunction of HPMECs by targeting the SRC pathway, providing a target for managing adult pneumonia.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.